Evidence map›Paper›PMID 33271968›Full record

ArticleBiomolecules2020

New Trends for Antimalarial Drugs: Synergism between Antineoplastics and Antimalarials on Breast Cancer Cells.

Diana Duarte, Nuno Vale

Open access · goldAbstract read
In one paragraph

Article in Biomolecules, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
2.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Metformin Impairs Linsitinib Anti-Tumor Effect on Ovarian Cancer Cell Lines.International journal of molecular sciences · 2024
    Article
  10. Article
  11. Chloroquine and Chemotherapeutic Compounds in Experimental Cancer Treatment.International journal of molecular sciences · 2024
    Review
  12. Anti-tumor mechanism of artesunate.Frontiers in pharmacology · 2024
    Review
  13. Article
  14. Article
  15. Article
  16. Antiparasitic Activity ofMicroorganisms · 2023
    Article
  17. Fractions 14 and 36K of Metabolite ExtractInfection and drug resistance · 2023
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Diana DuarteOncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Plácido da Costa, 4200-450 Porto, Portugal.ORCID 0000-0003-1420-5042
Nuno ValeOncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Plácido da Costa, 4200-450 Porto, Portugal.ORCID 0000-0002-1283-1042
Universidade do Porto · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemotherapy plays a key role in breast cancer therapy, but drug resistance and unwanted side effects make the treatment less effective. We propose a new combination model that combines antineoplastic drugs and antimalarials for breast cancer therapy. Cytotoxic effects of two antineoplastic agents alone and in combination with several antimalarials on MCF-7 tumor cell line was evaluated. Different concentrations in a fixed ratio were added to the cultured cells and incubated for 48 h. Cell viability was evaluated using MTT and SRB assays. Synergism was evaluated using the Chou-Talalay method. The results indicate doxorubicin (DOX) and paclitaxel (PTX) alone at concentrations of their IC

Indexed as

AntimalarialsAntineoplastic AgentsBreast NeoplasmsCell SurvivalDrug SynergismPaclitaxelAntineoplastic Combined Chemotherapy ProtocolsArtesunateCell ProliferationChloroquineDoxorubicinFemaleHumansMCF-7 CellsMefloquineAntimalarialsAntineoplastic AgentsArtesunateChloroquineDoxorubicinMefloquinePaclitaxelantimalarial drugsantineoplastic drugsbreast cancercombination therapydrug repurposingdrug synergism

Identifiers

PMID33271968
PMCPMC7761440
OpenAlexW3110259941

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.